Oxford BioMedica -  Interview with UK's Leading Gene Therapy Company for Comment on Genetics White Paper

June 24 2003. A big expansion in the use of gene therapy to tackle medical problems is expected to be announced by new Health Secretary John Reid in a Genetics White Paper today at 1.30pm.

 

Oxford BioMedica, founded in 1995 by Professor Alan Kingsman and Dr Sue Kingsman, is the UK's leading gene therapy company, listed on the London Stock Exchange. The Company has two gene-based products in Phase II clinical trials to treat colorectal cancer (a therapeutic vaccine) and breast cancer (a pro-drug) and a treatment for Parkinson's disease in late stage preclinical trials.  If you would like to set up an interview with Professor Alan Kingman, CEO, he will be available for interview in person or by telephone.

Northbank Communications Ltd The Media Centre, 131-151 Great Titchfield Street, London, W1W 5BB

Tel: +44 (0)20 7886 8150 Dir: +44 (0)20 7886 8153 Fax: +44 (0)20 7886 8151 Mobile: +44 (0)7789 435990 Email: k.stout@northbankcommunications.com